Neuropathix, Inc.
NPTX · OTC
3/31/2022 | 12/31/2021 | 9/30/2021 | 6/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -0.17 | 0.36 | 0.08 |
| FCF Yield | -3.62% | 0.21% | -2.33% | -2.53% |
| EV / EBITDA | 8.72 | -8.88 | -15.25 | -19.15 |
| Quality | ||||
| ROIC | -39.43% | 49.18% | 47.43% | 63.63% |
| Gross Margin | 100.00% | 100.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.07 | 0.04 | 0.20 | 0.36 |
| Growth | ||||
| Revenue 3-Year CAGR | 67.32% | 13.34% | -45.25% | -46.51% |
| Free Cash Flow Growth | -1,476.06% | 105.78% | 48.29% | 39.12% |
| Safety | ||||
| Net Debt / EBITDA | 3.40 | -2.87 | -3.55 | -2.54 |
| Interest Coverage | 1.83 | -9.32 | -4.48 | -5.98 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.17 | 0.24 | 0.00 | 0.00 |